scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0378-5173(00)00617-7 |
P698 | PubMed publication ID | 11165091 |
P2093 | author name string | J M Alvarez | |
S H Yalkowsky | |||
P Simamora | |||
P433 | issue | 1-2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | sirolimus | Q32089 |
P304 | page(s) | 25-29 | |
P577 | publication date | 2001-02-01 | |
P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
P1476 | title | Solubilization of rapamycin | |
P478 | volume | 213 |
Q36976738 | A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. |
Q37698614 | A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. |
Q37228071 | A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome |
Q58749798 | Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets |
Q73019454 | An intravenous formulation decision tree for discovery compound formulation development |
Q50968471 | Antifibrotic effect of rapamycin containing polyethylene glycol-coated alginate microcapsule in islet xenotransplantation. |
Q47171615 | Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer In Vivo |
Q46605325 | Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo. |
Q92407803 | Biomimetic Nanotherapies: Red Blood Cell Based Core-Shell Structured Nanocomplexes for Atherosclerosis Management |
Q38741022 | Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment |
Q46642455 | Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. |
Q36579890 | Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter |
Q39379576 | Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice |
Q39782546 | Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells |
Q50847738 | Development and evaluation of magnetic microemulsion: tool for targeted delivery of camptothecin to BALB/c mice-bearing breast cancer. |
Q42012873 | Development and physicochemical characterization of sirolimus solid dispersions prepared by solvent evaporation method |
Q43607993 | Eco-solvents--cluster-formation, surfactantless microemulsions and facilitated hydrotropy |
Q51732167 | Effect of nonionic surfactants in release media on accelerated in-vitro release profile of sirolimus eluting stents with biodegradable polymeric coating. |
Q37227448 | Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo |
Q57920928 | Electrospun Rapamycin-Eluting Polyurethane Fibers for Vascular Grafts |
Q47862043 | Eluting characteristics of a platelet glycoprotein receptor antibody using a PLLA-coated stent. |
Q38754057 | Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes |
Q35592271 | Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. |
Q39517953 | Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy |
Q43410189 | Enhanced solubility and oral absorption of sirolimus using D-α-tocopheryl polyethylene glycol succinate micelles |
Q85232310 | Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e |
Q50238528 | Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy |
Q38007998 | Exploiting p70 S6 kinase as a target for ovarian cancer |
Q37970730 | Has nanotechnology led to improved therapeutic outcomes? |
Q37435382 | Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. |
Q38340831 | Immunosuppressive drug therapy--biopharmaceutical challenges and remedies |
Q58606481 | Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis |
Q38735119 | Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin. |
Q64118316 | Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye |
Q30425418 | Localized ultrasound enhances delivery of rapamycin from microbubbles to prevent smooth muscle proliferation |
Q37539595 | Microbial synthesized biodegradable PHBHHxPEG hybrid copolymer as an efficient intracellular delivery nanocarrier for kinase inhibitor |
Q59808061 | Multifunctional Platinum@BSA–Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation |
Q38119471 | Multifunctional nanomicellar systems for delivering anticancer drugs. |
Q57366868 | Multiple noncovalent interactions mediated one-pot therapeutic assemblies for the effective treatment of atherosclerosis |
Q47351188 | Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies |
Q36920414 | Nanomedicines in renal transplant rejection--focus on sirolimus |
Q34512297 | Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery |
Q36805040 | Optimized formulation of solid self-microemulsifying sirolimus delivery systems |
Q41841053 | Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. |
Q35972736 | Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy |
Q36549331 | Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease |
Q36305452 | Prospective pilot study on combined use of pulsed dye laser and 1% topical rapamycin for treatment of nonfacial cutaneous capillary malformation |
Q37610134 | Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. |
Q35012339 | Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy |
Q88261423 | Rapamycin reduces Drosophila longevity under low nutrition |
Q64965492 | Selective substitution of 31/42-OH in rapamycin guided by an in situ IR technique. |
Q38475312 | Solid dispersion formulations of megestrol acetate with copovidone for enhanced dissolution and oral bioavailability |
Q35087664 | Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin |
Q37041259 | Switchable elastin-like polypeptides that respond to chemical inducers of dimerization |
Q48362769 | TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin |
Q92975644 | The Effect of Fluid Shear Stress on the In Vitro Release Kinetics of Sirolimus from PLGA Films |
Q38852662 | The Emerging Role of Nanotechnology in Cell and Organ Transplantation |
Q45902882 | The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems. |
Q41953034 | Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). |
Q52813151 | Yeast Gup1(2) Proteins Are Homologues of the Hedgehog Morphogens Acyltransferases HHAT(L): Facts and Implications. |
Search more.